Invitrogen™ hu14.18-IL2 Biosimilar Recombinant Monoclonal Antibody

Hu14.18-IL2 is a humanized monoclonal antibody covalently linked to two interleukin-2 (IL-2) molecules. The hu14.18 component specifically targets GD2, a disialoganglioside abundantly expressed on tumor cells, especially in neuroblastoma and melanoma. Meanwhile, IL-2 stimulates the proliferation and activation of immune cells such as natural killer (NK) cells and T cells. GD2, also known as GD2 ganglioside, is a tumor-associated glycolipid antigen that is overexpressed in a variety of cancers, particularly those derived from neuroectodermal tissues. Structurally, GD2 contains three carbohydrate residues and two sialic acids bonded to a ceramide tail, which is embedded in the outer plasma membrane. This compound plays a critical role in cell surface glycosylation changes during malignant transformation and is ranked high as a target for cancer vaccine development.